文献速递神经肿瘤

声动力疗法治疗胶质瘤的研究综述

Sonodynamic therapy for gliomas.
PubMed 文献 · J Neurooncol · 2021-07-12

本文综述了截至2021年1月Pubmed/MEDLINE收录的声动力疗法(SDT)治疗胶质瘤的细胞与动物研究。SDT通过全身给予声敏剂并经低频超声激活产生活性氧和自由基或破坏细胞膜而杀伤肿瘤。临床前研究显示SDT可控制肿瘤并延长生存且避免损伤周围脑组织,尚无完成的临床试验,但已有试验启动。

要点

  • SDT是声敏剂经低频超声激活后产生细胞毒作用的胶质瘤新疗法。
  • 卟啉和呫吨衍生物是有效的声敏剂,活性氧和自由基是主要杀伤机制。
  • 临床前研究显示SDT可控制肿瘤并延长生存,尚无完成的临床试验。

核心结论

  • 细胞与动物模型的临床前研究表明SDT是治疗胶质瘤有前景的方法。
  • 需进一步研究确定胶质瘤的最佳超声参数和声敏剂。
  • 胶质瘤及其他恶性脑肿瘤患者的SDT临床试验正在进行中。

研究设计与样本

  • 综述Pubmed/MEDLINE中2021年1月前发表的SDT治疗胶质瘤细胞培养和动物模型文献。

主要发现

  • 多种卟啉和呫吨衍生物被证明是有效的声敏剂。
  • 水热解或声敏剂产生活性氧和自由基,或细胞膜物理失稳,是SDT导致细胞死亡的机制。
  • 多种胶质瘤细胞系研究记录了SDT的杀肿瘤效应。
  • 小动物胶质瘤异种移植模型研究一致显示SDT与更好的肿瘤控制和更长的动物生存相关,同时避免周围脑组织损伤。

关键数值与推荐

  • 卟啉和呫吨衍生物是有效的声敏剂。
  • SDT通过活性氧和自由基生成或细胞膜物理失稳导致细胞死亡。
  • 小动物胶质瘤异种移植模型中SDT与更好的肿瘤控制和更长的生存相关,且避免周围脑损伤。

临床怎么用

  • 目前SDT尚未完成胶质瘤患者安全性和有效性的临床试验,临床决策应基于现有标准治疗。
  • 临床前证据支持SDT作为胶质瘤潜在治疗方向,可关注正在进行的临床试验。

局限性

  • 截至2021年1月尚无完成的SDT治疗胶质瘤患者的安全性和有效性临床试验。
  • 最佳超声参数和声敏剂尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glioma remains incurable and a life limiting disease with an urgent need for effective therapies. Sonodynamic therapy (SDT) involves systemic delivery of non-toxic chemical agents (sonosensitizers) that accumulate in tumor cells or environment and are subsequently activated by exposure to low-frequency ultrasound to become cytotoxic agents. Herein, we discuss proposed mechanisms of action of SDT and provide recommendation for future research and clinical applications of SDT for gliomas. METHODS: Review of literature of SDT in glioma cell cultures and animal models published in Pubmed/MEDLINE before January, 2021. RESULTS: Different porphyrin and xanthene derivatives have proven to be effective sonosensitizers. Generation of reactive oxygen species and free radicals from water pyrolysis or sonosensitizers, or physical destabilization of cell membrane, have been identified as mechanisms of SDT leading to cell death. Numerous studies across glioma cell lines using various sonosensitizers and ultrasound parameters have documented tumoricidal effects of SDT. Studies in small animal glioma xenograft models have also consistently documented that SDT is associated with improved tumor control and longer survival of animals treated with SDT while avoiding damage of surrounding brain. There are no clinical trials completed to date regarding safety and efficacy of SDT in patients harboring gliomas, but some are beginning. CONCLUSIONS: Pre-clinical studies cell cultures and animal models indicate that SDT is a promising treatment approach for gliomas. Further studies should define optimal sonication parameters and sonosensitizers for gliomas. Clinical trials of SDT in patients harboring gliomas and other malignant brain tumors are currently underway.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Bunevicius A, Pikis S, Padilla F, et al. Sonodynamic therapy for gliomas. J Neurooncol. 2021. PMID: 34251601. doi:10.1007/s11060-021-03807-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。